Quest Diagnostics ( NYSE: DGX), the world's leading provider of diagnostic information services,  announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the company's lab-developed molecular diagnostic test to aid in the diagnosis of infection with the Monkeypox virus.

The EUA is the first granted to a commercially available monkeypox test in the United States. On September 7, the Department of Health and Human Services declared that the public health emergency countermeasures now extend to monkeypox testing.

"Quest is committed to developing high-quality diagnostic innovations to help respond to the monkeypox public health emergency," said Jay G. Wohlgemuth, M.D., Senior Vice President, R&D, Medical and Chief Medical Officer, Quest Diagnostics. "With this FDA emergency authorization, Quest is positioned to complement the response of public health laboratories and help fight the spread of the virus."

The Quest Diagnostics Monkeypox Virus Qualitative Real-Time PCR ("Quest Monkeypox PCR") is intended for the qualitative detection of Monkeypox virus (West African clade, clade II) DNA and non-variola Orthopoxvirus DNA in lesion swab specimens (i.e., swabs of acute pustular or vesicular rash) in universal viral transport media from individuals suspected of Monkeypox virus infection by their healthcare provider. Test results are intended to be used in conjunction with patient history and other diagnostic information, and results should not be used as the sole basis of treatment or other patient management decisions.

Quest launched the Quest Monkeypox PCR test nationwide on July 13, 2022. The company performs the test at its advanced laboratories in San Juan Capistrano, Calif., and, beginning last week, Chantilly, VA, for ready access for providers and patients on both coasts of the United States. New York's Department of Health has approved the tests from both laboratories, enabling access for patients living in the state.

Developed with the understanding that viruses mutate, the Quest Monkeypox PCR test features the ability to detect two different DNA targets (Monkeypox and non-variola Orthopoxvirus DNA) to help protect against false negatives. On September 2, the Centers for Disease Control and Prevention issued a Lab Alert that certain monkeypox tests may fail to detect monkeypox infection when a rare deletion of the target gene (called tumor necrosis factor) occurs, and negative results for highly suspicious cases therefore require confirmation by the CDC or public health labs. The alert does not apply to the Quest Monkeypox PCR test, so Quest does not need to modify its test or refer specimens producing negative results to the CDC or public health labs for confirmation.